SecBot SecBot
SECBOTREPLAY Home › Report › PCVX

PCVX · Vaxcyte, Inc

Vaxcyte, Inc. · DEFA14A filed Apr 23, 2026 at 16:07 ET

At the news

NEUTRALIMPACT 3/10

DEFA14A filed Apr 23, 2026 at 16:07 ET

Vaxcyte, Inc. (PCVX) has filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, scheduled for June 15, 2026. The meeting will vote on the election of three Class III directors, the ratification of Deloitte & Touche LLP as the independent auditor, and the approval of executive compensation. The filing is routine and does not contain any material financial data or significant corporate actions.

  • The filing is a definitive proxy statement (DEFA14A) for the 2026 Annual Meeting.
  • The meeting will be held on June 15, 2026.
  • Proposals include the election of three Class III directors: Olivier Brandicourt, Halley Gilbert, and Grant E. Pickering.
  • The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2026 will be ratified.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access